Robert Dubiel

Idarucizumab for Dabigatran Reversal

Charles V. Pollack, Paul A. Reilly, John W. Eikelboom et al. · New England Journal of Medicine · 2015 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +4

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Charles V. Pollack, Paul Reilly, Joanne van Ryn et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Paul A. Reilly, Richard A. Bernstein, Robert Dubiel et al. · Thrombosis and Haemostasis · 2015 · 154 citations

Medicine, Pharmacology, Pharmacotherapy +17

Use of 24-Hour Ambulatory Blood Pressure Monitoring to Assess Antihypertensive Efficacy

David H.G. Smith, Robert Dubiel, Michael E. Jones · American Journal of Cardiovascular Drugs · 2005 · 115 citations

Medicine, Internal Medicine, Pharmacotherapy +12

A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.

Thomas Littlejohn, William J. Mroczek, Thomas Marbury et al. · PubMed · 2000 · 72 citations

Medicine, Pharmacology, Pharmacotherapy +15